Skip to main content

Peer Review reports

From: Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

Original Submission
30 Mar 2018 Submitted Original manuscript
30 May 2018 Reviewed Reviewer Report - Michael E. Rytting
23 Jul 2018 Reviewed Reviewer Report - Reviewer 2
30 Aug 2018 Author responded Author comments - Luca Bertamini
Resubmission - Version 2
30 Aug 2018 Submitted Manuscript version 2
24 Sep 2018 Reviewed Reviewer Report - Michael E. Rytting
30 Oct 2018 Author responded Author comments - Luca Bertamini
Resubmission - Version 3
30 Oct 2018 Submitted Manuscript version 3
Publishing
31 Oct 2018 Editorially accepted
15 Nov 2018 Article published 10.1186/s12885-018-5026-x

You can find further information about peer review here.

Back to article page